[A case of paclitaxel-induced peripheral neuropathy successfully treated by H2-blocker, lafutidine].
We report a 75-year-old female gastric cancer patient with paclitaxel-induced peripheral neuropathy, which was successfully treated by the H2-blocker, lafutidine. From December 2007, she underwent second-line chemotherapy using paclitaxel (80 mg/m/2 day 1, 7, 14/28 days) for peritoneal dissemination which had been refractory to first-line chemotherapy using S-1 (80 mg/m / 2, day 1-28/42 days). After 2 courses, CT showed a complete response (CR) of the peritoneal dissemination. However, at the same time peripheral neuropathy appeared, which was aggravated to grade 3 at the 6th course. Beginning with the 7th course, we administered lafutidine (10 mg/day) for peripheral neuropathy, which recovered to grade 1 after 14 days of lafutidine administration. Lafutidine was administered until July 2008, when peripheral neuropathy kept grade 1 without lafutidine. After 9 courses, paclitaxel therapy failed because of general fatigue.
Matsumura
Tae
T
Dept. of Surgery, Sakai Municipal Hospital.
Imamura
Hiroshi
H
Kishimoto
Tomono
T
Miyazaki
Yasuhiro
Y
Fujii
Chika
C
Fujino
Misako
M
Yasui
Yukako
Y
Anami
Setsuko
S
Sumita
Rumi
R
Takada
Natsuko
N
Fujita
Yuuko
Y
Furukawa
Hiroshi
H
D000081:Acetamides / Q000627:therapeutic use*; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D005260:Female; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D017239:Paclitaxel / Q000009:adverse effects*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy
D000081:Acetamides; D000972:Antineoplastic Agents, Phytogenic; D006635:Histamine H2 Antagonists; D010880:Piperidines; D011725:Pyridines; C076948:lafutidine; D017239:Paclitaxel